https://www.selleckchem.com/pr....oducts/CP-690550.htm
udies to verify the findings would be warranted. Glypican-1 is a heparan sulfate proteoglycan that is overexpressed in prostate cancer (PCa), and a variety of solid tumors. Importantly, expression is restricted in normal tissue, making it an ideal tumor targeting antigen. Since there is clinical and preclinical evidence of the efficacy of Bispecific T cell Engager (BiTE) therapy in PCa, we sought to produce and test the efficacy of a GPC-1 targeted BiTE construct based on the Miltuximab sequence. Miltuximab is a clinical stage anti-GP
Like
Comment
Share
